tiprankstipranks
Trending News
More News >
Invex Therapeutics Ltd. (AU:IXC)
ASX:IXC
Australian Market

Invex Therapeutics Ltd. (IXC) AI Stock Analysis

Compare
2 Followers

Top Page

AU

Invex Therapeutics Ltd.

(Sydney:IXC)

Rating:57Neutral
Price Target:
Invex Therapeutics Ltd. shows strong technical momentum, but faces significant financial challenges, particularly with profitability. The stock is trading above key moving averages, yet the high P/E ratio and lack of dividends suggest overvaluation risks. Despite a stable balance sheet, the negative income and cash flow issues weigh on the overall score.

Invex Therapeutics Ltd. (IXC) vs. iShares MSCI Australia ETF (EWA)

Invex Therapeutics Ltd. Business Overview & Revenue Model

Company DescriptionInvex Therapeutics Ltd. (IXC) is a biopharmaceutical company focused on the development and commercialization of treatments for neurological conditions. The company is primarily engaged in the research and development of innovative therapeutics targeting diseases with high unmet medical needs, particularly those related to intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH). Through its scientific expertise and innovative approach, Invex aims to deliver effective solutions that improve patient outcomes and quality of life.
How the Company Makes MoneyInvex Therapeutics Ltd. generates revenue through the development and potential commercialization of its pharmaceutical products. The company's primary revenue streams include licensing agreements and strategic partnerships with other pharmaceutical companies for the development and distribution of its pipeline products. Invex may also receive milestone payments and royalties from these collaborations, contingent upon the successful development and commercialization milestones. Additionally, the company might pursue government grants or funding from research institutions to support its R&D activities. As Invex progresses through clinical trials and moves closer to product approval and market entry, it aims to establish sustainable revenue channels through product sales and expanded partnerships.

Invex Therapeutics Ltd. Financial Statement Overview

Summary
Invex Therapeutics Ltd. is in a development phase with growing revenues but still faces significant challenges in achieving profitability. The balance sheet is strong with zero debt, but ongoing losses impact overall financial health. Cash flow management is improving, but negative net income continues to weigh heavily on cash positions.
Income Statement
45
Neutral
Invex Therapeutics Ltd. has shown improvements in revenue generation, with a significant increase in total revenue from 2022 to 2023. However, the company is still operating at a loss, as indicated by negative net income and EBIT margins. The gross profit margin is strong at 100%, but the net profit margin is negative due to high operating expenses.
Balance Sheet
60
Neutral
The company maintains a strong equity position with no debt, resulting in a commendable debt-to-equity ratio of 0. The equity ratio remains high, indicating stability. However, the return on equity is negative due to ongoing net losses, which is a concern for profitability.
Cash Flow
50
Neutral
The cash flow statements show a reduction in free cash flow losses, which suggests improving operational efficiency. Nonetheless, the operating cash flow to net income ratio remains negative, indicating that net income losses are affecting cash flow. The absence of capital expenditures is a positive in maintaining cash reserves.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
1.21M1.21M459.08K182.25K0.000.00
Gross Profit
1.21M1.21M459.08K182.25K0.000.00
EBIT
-116.47K-2.13M-8.55M-4.03M-2.44M-3.29M
EBITDA
-741.37K-720.44K0.000.000.000.00
Net Income Common Stockholders
114.36K-1.64M-7.75M-3.95M-2.28M-3.36M
Balance SheetCash, Cash Equivalents and Short-Term Investments
6.15M6.03M22.47M29.34M32.72M26.30M
Total Assets
6.28M6.12M22.80M29.49M32.74M26.42M
Total Debt
0.000.000.000.000.000.00
Net Debt
-6.15M-6.03M-22.47M-29.34M-32.72M-26.30M
Total Liabilities
984.57K431.63K1.57M1.00M658.61K2.02M
Stockholders Equity
5.30M5.69M21.23M28.48M32.08M24.40M
Cash FlowFree Cash Flow
-368.36K-2.44M-6.87M-3.38M-1.68M-1.60M
Operating Cash Flow
-368.36K-2.44M-6.87M-3.38M-1.68M-1.60M
Investing Cash Flow
0.000.000.000.000.000.00
Financing Cash Flow
0.00-14.00M0.000.008.09M15.73M

Invex Therapeutics Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.09
Price Trends
50DMA
0.08
Positive
100DMA
0.08
Positive
200DMA
0.08
Positive
Market Momentum
MACD
<0.01
Positive
RSI
56.97
Neutral
STOCH
-50.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IXC, the sentiment is Positive. The current price of 0.09 is below the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.97 is Neutral, neither overbought nor oversold. The STOCH value of -50.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IXC.

Invex Therapeutics Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUNAN
69
Neutral
$1.31B78.759.23%10.79%5.20%
AUIXC
57
Neutral
AU$6.99M62.002.14%
AURAC
54
Neutral
AU$205.88M-37.20%32.02%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
AUAGH
45
Neutral
AU$21.39M-218.38%-14.30%29.69%
AUBIT
36
Underperform
$3.32M-119.28%64.10%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:IXC
Invex Therapeutics Ltd.
0.09
0.02
28.57%
AU:BIT
Biotron
0.01
-0.04
-78.00%
AU:NAN
Nanosonics Limited
4.30
1.47
51.94%
AU:RAC
Race Oncology Ltd.
1.18
-0.72
-37.89%
AU:AGH
Althea Group Holdings Ltd.
0.03
<0.01
50.00%

Invex Therapeutics Ltd. Corporate Events

Invex Therapeutics Expands Alzheimer’s Research Collaboration and Reports Financial Stability
Apr 8, 2025

Invex Therapeutics Ltd announced an expansion of its research collaboration with Tessara Therapeutics to further investigate the effects of Exenatide on Alzheimer’s Disease models, aiming to gain insights into its potential benefits on neural networks and gene expression. The company also reported prudent cash management with a closing balance of $5.7 million and highlighted a UK R&D tax incentive receipt, while continuing to explore additional asset opportunities.

Invex Therapeutics Updates Registered Office Address
Feb 20, 2025

Invex Therapeutics Ltd announced a change of its registered office address, now located at Level 5, 191 St Georges Terrace, Perth WA 6000. This relocation is part of compliance with ASX Listing Rule 3.14, and all other contact information remains unchanged. The announcement reflects ongoing organizational adjustments, which could have implications for its operational efficiencies and stakeholder communications.

Invex Therapeutics Reports Reduced Losses but Withholds Dividends
Feb 6, 2025

Invex Therapeutics Ltd reported a significant decrease in other income and a substantial reduction in net loss for the half-year ending December 31, 2024, compared to the previous year. Despite the financial improvements, the company has not declared any dividends for the period, indicating a cautious approach in maintaining financial stability and potentially reinvesting in its operations.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.